NCT07796841Not yet recruiting
GAS5 Gene Expression and IL-6 in Rheumatoid Arthritis
Expression of Growth Arrest-Specific 5 (GAS5) Long Non-Coding RNA and Serum Interlukin-6 Levels in Patients With Rheumatoid Arthritis
Source: ClinicalTrials.gov · Last updated 1 Sept 2026
Brief summary (registry, in English)
This study aims to investigate the expression of Growth Arrest-Specific 5 (GAS5) , a long non-coding RNA , in patients with Rheumatoid Arthritis compared with healthy individuals. The study will also assess the level of Interlukin-6 (IL-6) in the blood and explore the relationship between GAS5 expression and IL-6 levels in Rheumatoid Arthritis
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 50 (estimated)
- First submitted
- 27 Aug 2026
- Start date
- Oct 2026
- Primary completion date
- Oct 2027
- Lead sponsor
- Sohag University
- Diseases
- Rheumatoid arthritis
- NCT number
- NCT07796841
What you commit to
- Study type: Observational
- Planned participants: 50
- From Oct 2026 to the primary completion date, Oct 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who did not meet the previous inclusion criteria
Who the study is looking for
- Adult patients older than 18 years patients diagnosed with Rheumatoid Arthritis according to the 2010 American collage Rheumatology / European League against Rheumatism (ACR/EULAR) classification criteria
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.